Keros Therapeutics, Inc. (KROS) is a Biotechnology company in the Healthcare sector, currently trading at $11.55. It has a SharesGrow Score of 78/100, indicating a strong investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of KROS = $2,886.14 (+24888.2% from the current price, the stock appears undervalued). Analyst consensus target is KROS = $103 (+788.3% upside).
Valuation: KROS trades at a trailing Price-to-Earnings (P/E) of 5.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.3.
Financials: revenue is $244M, +4513%/yr average growth. Net income is $87M, growing at +25.9%/yr. Net profit margin is 35.7% (strong). Gross margin is 99.4% (+539.1 pp trend).
Balance sheet: total debt is $17M against $303M equity (Debt-to-Equity (D/E) ratio 0.06, conservative). Current ratio is 15.45 (strong liquidity). Debt-to-assets is 5%. Total assets: $338M.
Analyst outlook: 9 / 16 analysts rate KROS as buy (56%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 25/100 (Fail), Health 100/100 (Pass), Moat 58/100 (Partial), Future 64/100 (Pass), Income 100/100 (Pass).
